Year: 2024
Type: article
Abstract: adding venetoclax (or perhaps other active agents) to pirtobrutinib may improve the durability of disease control over monotherapy.Roeker et al have combined pirtobrutinib with venetoclax (PV), with or without additional rituximab (PVR).They demonstrated that this combination is both well tolerated and has impressive activity.The overall response rates were 93.3% (95% confidence interval [CI], 68.1% to 99.8%) for PV and 100% (95% CI, 69.2% to 100.0%) for PVR, with 10 complete responses (PV, 7; PVR, 3).After 12 cycles of treatment, 85.7% (95% CI, 57.2% to 98.2%) of PV and 90.0%(95% CI, 55.5% to 99.7%) of PVR patients achieved undetectable minimal residual disease in peripheral blood by clonoSEQ assay (Labcorp, Burlington, NC) at a sensitivity of <1 × 10 -4 .Progression-free survival at 18 months was 92.9% (95% CI, 59.1% to 99.0%) for PV patients and 80.0% (95% CI, 40.9% to 94.6%) for PVR patients.This phase 1B trial has provided the key combination data for a large registration study that is currently enrolling patients.In the forthcoming study, patients with relapsed CLL will be randomly assigned to venetoclax and rituximab, with or without the addition of pirtobrutinib.Paul Ehrlich, the remarkable visionary whose work helped set the stage for cancer medicine, would likely be pleased that we are still pursuing his ideas over 100 years later.
Source: Blood
Authors: Juliane Gust, Nirali N. Shah
Institutions: Seattle Children's Hospital, National Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: G8168027453
OpenAlex ID: W4402860190